CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

F. Johnson, Shawn; Cruz, Cristina; Katrin Greifenberg, Ann; Dust, Sofia; G. Stover, Daniel; Chi, David; Primack, Benjamin; A. Cao, Shiliang; J. Bernhardy, Andrea; Coulson, Rhiannon; Lazaro, Jean‐Bernard; Kochupurakkal, Bose; H. Sun, Heather; Unitt, Christine; A. Moreau, Lisa; A. Sarosiek, Kristopher; Scaltriti, Maurizio; Juric, Dejan; Baselga, José; L. Richardson, Andrea; J. Rodig, Scott; D. D’Andrea, Alan; Balmañà, Judith; Johnson, Neil; Geyer, Matthias; Serra, Violeta; Lim, Elgene; I. Shapiro, Geoffrey

doi:10.1016/j.celrep.2016.10.077

Public

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

Published in Cell Reports • Nov 1, 2016

Authors:

Shawn F. Johnson

Cristina Cruz

Ann Katrin Greifenberg

Abstract

Although poly(ADP-ribose) polymerase (PARP) inhibitors are active in homologous recombination (HR)-deficient cancers, their utility is limited by acquired resistance after restoration of HR. Here, we report that dinaciclib, an inhibitor of cyclin-dependent kinases (CDKs) 1, 2, 5, and 9, additionally...

Subject

PARP inhibitor

Triple-negative breast cancer

Cancer research

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!